Skip to main content

PhoRC—a New Approach Inducing Dephosphorylation of Target Proteins


Post-translational modifications (PTM), including ubiquitination, phosphorylation, methylation, lipidation and glycosylation, are important processes in protein maturity, which can influence the localization, activity, and stability of their conjugated proteins. In the past decade, proteolysis targeting chimera (PROTAC), a heterobifunctional small molecule consisting of a targeted protein binder, an E3 ligase binder and a linker, has been proved as a powerful chemical tool to degrade specific proteins. However, except ubiquitination, methods to manipulate other PTMs of proteins remain elusive. A recent paper in J. Med. Chem described a pioneering work of using a novel heterobifunctional molecule to induce dephosphorylation of a targeted kinase.

Phosphorylation is the prerequisite for the activities of kinases and their downstream signaling pathways. In contrast, dephosphorylation of kinases is an effective approach to inhibit kinase activities. In this paper, the researchers conjugated a reported PP1-activating synthetic peptide (PDP1), which binds a ubiquitously expressed phosphatase PP1, with a Protein kinase B (AKT) inhibitor via a PEG linker. This heterobifunctional molecule 3 greatly decreased the pAKTT308 levels in a recombinant biochemical system in a PPI-dose dependent manner. 

However, this molecule failed to change the cellular pAKTT308 levels due to its poor permeability or potential proteolytic instability. To address this problem, the authors synthesized another heterobifunctional molecule 4a with a shorter and better permeable PPI peptide. As anticipated, 4a greatly decreased the level of pAKTT308 and pAKTS473 in prostate cancer LNCaP cells at 10 µM, whereas the negative control 4b did not. Consistent with the previous biochemical assay, PP1 binder 6 could restore the levels of pAKTT308 and pAKTS473 through disrupting the ternary complex formation.


To test the generality of this targeted dephosphorylation strategy, the authors synthesized a bifunctional molecule 7 with a covalent EGFR inhibitor and a HaloTag reactive chloroalkane. As expected, 7 substantially decreased the pEGFRY1068 level in the HaloTag-PP1-FLAG transfected cells. 

Although the in vitro activities of the compounds developed in this study were not highly potent due to their poor permeabilities, this work expanded the applications of heterobifunctional molecule in manipulating PTMs of proteins and provided a good starting point to develop more potent phosphatase recruiting chimeras (PhoRCs). 
Reference: Yamazoe S, et. al. JHeterobifunctional Molecules Induce Dephosphorylation of Kinases-A Proof of Concept Study. J. Med. Chem. 2020, 63, 2807−2813.

Comments

Post a Comment

Popular posts from this blog

Lysine-Targeted Covalent Inhibitors Gaining Traction

In the past decade, targeted covalent inhibitors (TCIs) has experienced a resurgence due to its sustained target engagement and improved proteome-wide selectivity. Currently, targeting cysteine residues with acrylamides and other α, β-unsaturated carbonyl compounds is the predominant strategy in TCI development. Although lysine is more prevalent than cysteine and possesses lower mutation rates, lysine has been much less frequently considered and more challenging as a residue targeted by TCIs due to its low nucleophilicity. Recently, Jack Taunton and his colleagues reveled their two related work in JACS .   Based on the co-crystal structure of Hsp90 with a reversible inhibitor PU-H71, they designed two arylsulfonyl fluorides 1 and 2 and co-incubated them with Hsp90 protein (Figure 1a, b). Mass spectrometry detected the formation of a 1:1 covalent adduct. Mutation of Lys58 to arginine abrogated the covalent modification, indicating that the TCI selectively modified Lys58 (Fig...
Post a Comment
Read more

Multiple Postdoc and Technician Positions Available at Baylor College of Medicine

  Multiple postdoc and technician positions are available in Dr. Jin Wang’s group in the Department of Pharmacology and Chemical Biology at Baylor College of Medicine (BCM). BCM is located in the world largest medical center and has access to enormous biomedical resources. The research in the Wang lab is highly interdisciplinary and translational. The Wang lab has both chemistry and biology operations. For chemistry work, we have 17 chemical fume hoods, 4 ISCO combiflash chromatography systems, Agilent analytical LC-MS, Agilent preparative HPLC with auto-purification, and Genevac high throughput solvent evaporation, along with convenient access to 600 and 800 MHz NMR. For biology work, we have common equipment for biochemistry, molecular and cell biology, including tissue culture hoods, RT-PCR, plate reader, and imaging plate reader, and perform animal work to evaluate the efficacy of the experimental therapeutics developed in the group. In addition, we recently acquired a state-...
Post a Comment
Read more

RIPK2 PROTAC Burns up the Bridges between PK and PD

GlaxoSmithKline (GSK) previously reported a series of RIPK2 PROTACs with various E3 ligase binders (Figure 1). These PROTACs can degrade RIPK2 potently and efficiently in a concentration-dependent manner (Figure1). However, their poor solubility and high microsomal clearance limited their in vivo applications. To develop a RIPK2 degrader suitable for  in vivo  applications, the GSK group identified another IAP based RIPK2 PROTAC4 that is significantly different from PROTAC2, possessing a different RIPK2 binder, IAP ligase binder and linker (Figure2). PTROTAC4 can degrade RIPK2 in a time-dependent manner and shows reduced lipophilicity and lower clearance in hepatocytes. However, the modest binding affinity between the warhead of PROTAC4 and RIPK2 requires a high dose to reach efficient RIPK2 degradation. To address this limitation, the researchers performed extensive medicinal chemistry optimization based on PROTAC 4 and identified PROTAC 6 (Figure2), which contains an...
Post a Comment
Read more